Ali Raza Khaki MD (He/Him)
Hematology/Oncology
Clinical Assistant Professor
Join to View Full Profile
300 Pasteur DrStanford, CA 94305
Phone+1 650-723-4000
Dr. Khaki is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonMS, Epidemiology, 2019 - 2020
University of WashingtonFellowship, Hematology and Medical Oncology, 2017 - 2020
University of California (San Francisco)Residency, Internal Medicine, 2013 - 2016
University of California San Diego School of MedicineClass of 2013, MD, Member of Gold Humanism Honor Society- Carleton CollegeBA, Chemistry, Magna Cum Laude, 2003 - 2007
Certifications & Licensure
CA State Medical License 2014 - 2026
WA State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen
European Urology Oncology. 2025-04-01 - Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, Leonidas N Diamantopoulos, Thomas Enright
Clinical Genitourinary Cancer. 2025-02-01 - 1 citationsAssociation of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint I...Dimitra Rafailia Bakaloudi, Rafee Talukder, Dimitrios Makrakis, Leonidas Diamantopoulos, Thomas Enright
Clinical Genitourinary Cancer. 2024-12-01
Press Mentions
Adding Radioligand to Enzalutamide Boosts OS in Metastatic CRPCFebruary 14th, 2025- Cancer Patients More at Risk for Covid-19 Infection Than Those Without CancerDecember 14th, 2020
SCCA’s Immunotherapy Leaders Featured at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 31st, 2018
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
